BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively.
SN-001 is a STING inhibitor with an IC50 of 3.82 μM. SN-001 targets the cyclic dinucleotide binding pocket of human STING.
BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively.
Amikacin is a semi-synthetic kanamycin analog and an aminoglycoside antibiotic with antimicrobial activity against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains.
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289.
Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research.
(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M2-selective muscarinic receptor antagonist (pA2 = 7.86/7.74; pKi = 7.78). (S)-(+)-Dimethindene maleate also is a histamine H1 receptor antagonist (pA2 = 7.48).
(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M2-selective muscarinic receptor antagonist (pA2 = 7.86/7.74; pKi = 7.78). (S)-(+)-Dimethindene maleate also is a histamine H1 receptor antagonist (pA2 = 7.48).
Gepotidacin (GSK2140944) is a novel, potentially first-in-class, orally active triazaacenaphthylene antibiotic and type II topoisomerase (Topo II) inhibitor.Gepotidacin can selectively inhibit bacterial DNA replication by acting on DNA gyrase (GyrA) and topoisomerase IV (ParC).
Gepotidacin (GSK2140944) is a novel, potentially first-in-class, orally active triazaacenaphthylene antibiotic and type II topoisomerase (Topo II) inhibitor.Gepotidacin can selectively inhibit bacterial DNA replication by acting on DNA gyrase (GyrA) and topoisomerase IV (ParC).